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This Month in the Journal
This month in the Journal, Robert Hegele (p. 1161)
contributes a review on monogenic dyslipidemias. Af-
ter presenting an overview of lipoprotein metabolism,
Dr. Hegele describes known defects in these pathways
and the phenotypic outcomes of these defects. These
outcomes include disorders that affect the levels of LDL,
HDL, triglycerides, and remnant lipoproteins. He also
touches on whether common variation in the compo-
nents of these metabolic pathways will be useful for the
determination of cardiovascular risks in the general
population.
Mutations in FKRP Cause a Form of CMD, by
Brockington et al. (p. 1198)
The congenital muscular dystrophies (CMDs) are a group
of autosomal recessive disorders that are characterized by
hypotonia, muscle weakness, and dystrophic changes of
skeletal muscle. Although genes involved with some types
of CMD are known, there are forms of CMD for which
no underlying defect has been identified. Individuals with
Fukuyama CMD (FCMD) have mutations in the FCMD
gene, which encodes fukutin, and a secondary reduction
in the expression of laminin a2. FCMD is rare outside
Japan, but there are other forms of CMD that have sec-
ondary laminin a2 deficiencies. This led Brockington et
al. to look for FCMD-like genes that might be mutated
in other forms of CMD. Using the mouse FCMD se-
quence, they found a fukutin-related gene, in mice, and
its human ortholog. As with fukutin, human fukutin-re-
lated protein (FKRP) contains motifs suggestive of a sugar
transferase. Seven families with both a common, severe
CMD phenotype and a secondary laminin a2 deficiency
were found to have FKRP mutations. Muscle from af-
fected individuals shows a severe reduction in a-dystro-
glycan expression. The a-dystroglycan that is expressed
is of reduced molecular weight, and Brockington et al.
believe that this is due to a different pattern of glycosy-
lation in these patients and that this altered processing
plays a major role in the pathology of the disorder. Nor-
mal expression of other glycosylated proteins in muscle
suggests that this disorder does not result from a gener-
alized defect of glycosylated proteins, although as-yet-un-
identified alterations of other glycosylated proteins cannot
be ruled out as participating in the phenotype.
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Association-Based Substance-Abuse Genome Scan,
by Uhl et al. (p. 1290)
Although drug-abuse vulnerability has a significant ge-
netic component, it has been very difficult to localize genes
for complex behavioral disorders. Uhl et al. tackle this
problem with a genomewide-association approach. Be-
cause the number of markers required for such a study
is large, the authors pooled samples and genotyped them
in a high-throughput gene-chip assay. By first combining
the cases (individuals with a history of drug abuse) and
unrelated controls in separate pools, the researchers re-
duced the labor involved for this study, because they could
identify and individually examine only the interesting
markers: those that exhibited the largest allele-frequency
differences between the original pools of cases and con-
trols. The replication of allele-frequency differences be-
tween cases and controls in a second sample of a different
race allowed the authors to limit their attention to 42
markers that were reproducibly positive in the two sam-
ples. Of these 42 markers, 2 were !0.2 Mb from each
other, and one pair corresponded to the same SNP, thus
decreasing the likelihood that the associations were spu-
rious. A third pair of markers flanked a strong candidate-
gene locus, BDNF. This gene encodes brain-derived neu-
rotrophic factor, which influences both the development
and survival of certain classes of neurons and the ex-
pression of the dopamine D3 receptor. A polymorphism
inBDNF shows associationwith drug-abuse vulnerability
in this sample.
Bias in Locus Effect-Size Estimates, by Go¨ring et al.
(p. 1357)
Why is it so hard to replicate linkage and association
for complex traits, and why do most follow-up studies
give lower locus-specific effect-size estimates than are
seen in the original studies? Go¨ring et al. demonstrate,
through simulation and analytical results, that, if you
estimate the size of a locus-specific effect—such as phe-
notypic variance—at genomewide LOD-score peaks, the
result will tend to be grossly inflated. Because LOD
scores and locus-specific effect sizes are not independent,
if the LOD score is maximized across the genome, then
the locus-specific effect size is also maximized, and this
generates the upward bias. The conditions used for the
simulations include a fairly large data set, fully infor-
mative markers across the genome, and error-free data.
These conditions are unlikely to be met in a real genome
scan for complex disease, and the bias is likely to be
even greater. In fact, the bias in locus-specific effect-size
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estimation is inversely related to the power of a study.
The power to replicate gene-mapping results is likely to
be overestimated if inflated locus-specific effect-size es-
timates from an initial study are believed, and this could
lead to failure to replicate. There is no obvious correc-
tion for the bias in locus-specific effect estimates. The
authors urge that, to get around the bias, readers should
use independent data sets for locus mapping and for
estimation of locus-specific effect size.
CASQ2 Mutation in Autosomal Recessive PVT, by
Lahat et al. (p. 1378)
Catecholamine-induced polymorphic ventricular tachy-
cardia (PVT) is a stress-related ventricular tachycar-
dia—in the absence of structural heart disease—that usu-
ally presents as fainting episodes, seizures, or sudden
death in response to emotional or physical stress. Au-
tosomal dominant catecholamine-induced PVT has been
ascribed to mutations in RYR2, encoding a cardiac sar-
coplasmic–reticulum calcium-release channel that cou-
ples excitation of myocardial cells to the cardiac con-
tractile apparatus. Lahat et al. previously localized the
gene for an autosomal recessive catecholamine-induced
PVT to chromosome 1p13-p21. Now, they have refined
this interval and have discovered that therein lies a gene
that encodes another protein, calsequestrin 2, involved
in the control of calcium in the sarcoplasmic reticulum.
A D307H mutation segregates with disease in all of the
affected families. On the basis of a model of rabbit skel-
etal-muscle calsequestrin, the mutated residue protrudes
into an interdomain space that is thought to play an
important role in sequestration of calcium ions. The re-
placement of a negatively charged residue by a positively
charged one, as is seen with the mutation, would likely
disrupt calcium binding to this region. Further sup-
porting the association of D307H with disease is the fact
that mice overexpressing calsequestrin 2 have cardiac
abnormalities, features of which are similar to those seen
in patients carrying the D307H mutation.
Histone Methylation at the PWS-IC, by Xin et al.
(p. 1389)
Evidence of genetic imprinting at chromosome 15q11-
q13 is revealed when a copy of this genetic region is not
inherited from each parent. Because some genes in this
region are exclusively expressed from the maternal or pa-
ternal chromosome, loss of the allele from one parent
results in altered gene expression. Loss of the paternal
copy of the region, either through deletion or through
uniparental disomy, leads to Prader-Willi syndrome
(PWS), whereas loss of the maternal copy leads to An-
gelman syndrome (AS). The mechanism governing dif-
ferential gene expression from homologous chromosomes
is not understood. Xin et al. attempt to identify the epi-
genetic mark distinguishing the maternal from the pater-
nal alleles in this region. They examine histone methyl-
ation in this region because histone modifications are
known to affect transcription and heterochromatin as-
sembly and because histone methylation exhibits a low
turnover rate. Chromatin from individuals with PWS,
from individuals with AS, and from controls was im-
munoprecipitated with antibodies either to histonesmeth-
ylated at the lysine 9 residue or to those methylated at
the lysine 4 residue. Precipitated DNA was then assayed,
by PCR, for specific sequences in the imprinted chro-
mosome 15 region. Maternal-specific methylation of ly-
sine 9 of histoneH3was identified in a region surrounding
SNRPN exon 1, the maternal allele of which is inactive;
paternal-specific methylation of lysine 4 of histone H3
was seen for the promoters of SNRPN and NDN, genes
that are both paternally expressed. Thus, these markers
distinguish the parental alleles of these genes from each
other. These results suggest that histone modificationmay
be the imprint marker in this region, and Xin et al. pro-
pose a model by which this marker could be transferred
in a sex-specific manner during gametogenesis.
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